Literature DB >> 7636271

Sm and DNA binding by dual reactive B cells requires distinct VH, V kappa, and VH CDR3 structures.

M W Retter1, R A Eisenberg, P L Cohen, S H Clarke.   

Abstract

We have previously demonstrated an overlap of the anti-Sm and anti-DNA responses in MRL/Mp-lpr/lpr mice. The Ab produced by many anti-Sm hybridomas bind DNA and are encoded by Ig V genes used by anti-DNA hybridomas. In addition, some anti-Sm Ab that bind DNA have acquired mutations that improve DNA binding, indicating that DNA is a selecting Ag in the anti-Sm response. To gain insight into the basis for the dual binding ability of these Ab, we coexpressed the H chain from the anti-Sm hybridoma 2-12 with nine different L chains. Hybridoma 2-12 binds Sm but not DNA, yet expresses the same J558 VH gene as three anti-Sm hybridomas that bind ssDNA and at least one anti-DNA hybridoma that does not bind Sm. We found that most of the transfectoma Ab bind Sm, but their avidities vary over more than 3 orders of magnitude. Five of the nine transfectoma Ab bind ssDNA, and none bind dsDNA. In general, the ability to bind each Ag follows the binding ability of the hybridoma from which the L chain is derived. H Chain swapping experiments indicate that the H chain, VH CDR3 in particular, contributes to the binding of both Sm and DNA. We conclude that Sm and DNA select for distinct features of VH, V kappa, and VH CDR3, suggesting selection by both Ag in the anti-Sm response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636271

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  False-positive myeloperoxidase binding activity due to DNA/anti-DNA antibody complexes: a source for analytical error in serologic evaluation of anti-neutrophil cytoplasmic autoantibodies.

Authors:  H S Jethwa; P H Nachman; R J Falk; J C Jennette
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Macrophages prevent the differentiation of autoreactive B cells by secreting CD40 ligand and interleukin-6.

Authors:  Michelle A Kilmon; Nikki J Wagner; Alaina L Garland; Li Lin; Katja Aviszus; Lawrence J Wysocki; Barbara J Vilen
Journal:  Blood       Date:  2007-09-01       Impact factor: 22.113

Review 3.  B-cell anergy: from transgenic models to naturally occurring anergic B cells?

Authors:  John C Cambier; Stephen B Gauld; Kevin T Merrell; Barbara J Vilen
Journal:  Nat Rev Immunol       Date:  2007-07-20       Impact factor: 53.106

4.  Apoptotic Debris Accumulates on Hematopoietic Cells and Promotes Disease in Murine and Human Systemic Lupus Erythematosus.

Authors:  SunAh Kang; Jennifer L Rogers; Andrew J Monteith; Chuancang Jiang; John Schmitz; Stephen H Clarke; Teresa K Tarrant; Young K Truong; Marilyn Diaz; Yuri Fedoriw; Barbara J Vilen
Journal:  J Immunol       Date:  2016-04-08       Impact factor: 5.422

5.  Association between anti-nucleophosmin and anti-cardiolipin antibodies in (NZW x BXSB)F1 mice and human systemic lupus erythematosus.

Authors:  Aurelia Lartigue; Laurent Drouot; Fabienne Jouen; Roland Charlionet; François Tron; Danièle Gilbert
Journal:  Arthritis Res Ther       Date:  2005-10-13       Impact factor: 5.156

6.  Light chain usage in anti-double-stranded DNA B cell subsets: role in cell fate determination.

Authors:  L Spatz; V Saenko; A Iliev; L Jones; L Geskin; B Diamond
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

7.  Selection at multiple checkpoints focuses V(H)12 B cell differentiation toward a single B-1 cell specificity.

Authors:  C Tatu; J Ye; L W Arnold; S H Clarke
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

8.  A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice.

Authors:  S L Peng; M E Robert; A C Hayday; J Craft
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

9.  Receptor editing occurs frequently during normal B cell development.

Authors:  M W Retter; D Nemazee
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.